文献速递甲状腺疾病

甲状腺激素替代治疗停药后的临床结局:系统综述与Meta分析

Clinical Outcomes After Discontinuation of Thyroid Hormone Replacement: A Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2020-12-29

约三分之一患者停药后随访时仍保持甲状腺功能正常(37.2%,95%CI 24.2-50.1%,I2 97.5%),既往诊断为显性甲状腺功能减退者保持正常比例较低(11.8%,95%CI 0.4-23.2%),而亚临床甲状腺功能减退者较高(35.6%,95%CI 8.2-62.9%)。无研究采用系统性停药框架。

要点

  • 约37.2%患者停药后仍甲功正常,但证据质量低且异质性高。
  • 既往显性甲减者停药后甲功正常比例(11.8%)低于亚临床甲减者(35.6%)。
  • 目前缺乏系统性甲状腺激素停药框架,需规范患者选择与流程。

核心结论

  • 低质量证据提示最多约三分之一患者停药后仍保持甲状腺功能正常,亚临床甲减者比例高于显性甲减者。
  • 需建立聚焦患者选择和系统流程的甲状腺激素停药框架以指导临床再评估。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid MEDLINE、Embase、Cochrane数据库及Scopus至2020年2月。
  • 由评价者独立双份筛选文献、提取数据并评估方法学质量。

主要发现

  • 停药后随访时保持甲状腺功能正常的比例为37.2%(95%CI 24.2-50.1%,I2 97.5%)。
  • 既往显性甲减者保持甲功正常比例为11.8%(95%CI 0.4-23.2%,I2 90.3%),低于亚临床甲减者的35.6%(95%CI 8.2-62.9%,I2 94.0%)。
  • 评估的临床结局包括保持甲功正常或需重启替代治疗的比例、甲减症状频率及不良事件。
  • 无研究采用系统性甲状腺激素停药框架。

临床怎么用

  • 对考虑停用甲状腺激素的患者,应基于初始诊断评估停药成功可能性,显性甲减者成功概率较低。
  • 停药后需随访监测甲功及甲减症状,必要时重启替代治疗。
  • 目前缺乏标准化停药框架,临床决策应个体化并充分告知患者。

局限性

  • 纳入研究均为观察性研究,偏倚风险中至高。
  • 异质性高(I2最高达97.5%),合并估计值需谨慎解读。
  • 证据质量低,停药成功预测因素和框架证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Levothyroxine (LT4) is one of the most commonly prescribed medications. Although considered a life-long replacement therapy, LT4 therapy can be discontinued for some patients. This study aims at: (i) reviewing the evidence on clinical outcomes of patients undergoing thyroid hormone replacement discontinuation, (ii) identifying the predictors of successful discontinuation, and (iii) systematically appraising frameworks used for deprescribing thyroid hormone. Methods: We searched multiple bibliographic databases, including Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus, from inception to February 2020 for studies in which thyroid hormone replacement was discontinued. Clinical outcomes assessed included: proportion of patients that remained euthyroid or needed to restart thyroid hormone replacement after discontinuation and frequency of clinical symptoms of hypothyroidism and adverse effects. We also evaluated predictors for discontinuation and deprescribing frameworks. Reviewers (F.J.K.T., N.B., N.M.S.O., S.M.) evaluated studies for inclusion, extracted data, and assessed methodological quality independently and in duplicate. Results: Seventeen observational studies at moderate to high risk of bias met inclusion criteria, including a total of 1103 patients (86% women) with an age range of 2-81 years. Approximately a third of patients undergoing thyroid hormone discontinuation remained euthyroid at follow-up (37.2%, 95% confidence interval [CI 24.2-50.1%], I2 97.5%). Subgroup analysis showed that patients with a previous diagnosis of overt hypothyroidism (OH) were less likely to remain euthyroid (11.8% [CI 0.4-23.2%], I2 90.3%) than patients with a prior diagnosis of subclinical hypothyroidism (SCH) (35.6% [CI 8.2-62.9%], I2 94.0%). No study followed a framework for systematically deprescribing LT4. Conclusions: Low-quality evidence suggests that up to a third of patients remained euthyroid after thyroid hormone discontinuation, with a higher proportion of patients with an initial diagnosis of SCH remaining euthyroid than patients with an initial diagnosis of OH. A deprescribing framework focusing on adequate selection of patients for deprescribing LT4 and a systematic process is warranted to guide clinicians in re-evaluating the need for LT4 in their patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Burgos N, Toloza FJK, Singh Ospina NM, et al. Clinical Outcomes After Discontinuation of Thyroid Hormone Replacement: A Systematic Review and Meta-Analysis. Thyroid. 2020. PMID: 33161885. doi:10.1089/thy.2020.0679

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。